BillionToOne says it will expand its Unity Fetal Risk Screen NIPT and add a tissue-of-origin feature to its Northstar Select liquid biopsy assay, as Q2 revenue rises. The company is preparing to launch additional oncology and fetal screening add-ons tied to its existing assay systems. The expansion includes a more detailed Unity fetal risk screen program plus a new clinical capability aimed at therapy selection using tissue-of-origin insights derived from liquid biopsy inputs. For biotech stakeholders, the move underscores how diagnostics vendors are bundling new features onto platform tests to expand reimbursement conversations and widen addressable patient segments within women’s health and oncology.